Find Funding Opportunities

The purpose of this notice is to inform applicants of a change to the Key Dates for RFA-NS-18-023 "BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Required)". This Funding Opportunity Announcement has been extended by one council round. The dates have been modified to add a New Application Due Date of February 22, 2021.

The purpose of this notice is to inform applicants of a change to the Key Dates for RFA-NS-18-021 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Required)". This Funding Opportunity Announcement has been extended by one council round. The dates have been modified to add a New Application Due Date of February 22, 2021.

This FOA is intended to: (1) increase our understanding of how music positively affects the brain, body, and behavior and (2) use that knowledge to enhance health and/or treat specific diseases and disorders. Proposed R01 projects could investigate the mechanisms by which music affects the brain to improve health either in healthy or diseased states. Proposed R01 projects could also focus on the development or refinement of specific musical interventions relevant to the participating institutes, agencies, and offices. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

This FOA is intended to: (1) increase our understanding of how music positively affects the brain, body, and behavior and (2) use that knowledge to enhance health and/or treat specific diseases and disorders. R21 projects could propose exploratory investigations to define the mechanisms by which music affects the brain to improve health either in healthy or diseased states. Proposed R21 projects could explore the early stage development or refinement of specific musical interventions relevant to the participating institutes, agencies and offices. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

This Notice encourages eligible NINDS awardees in the Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research community to apply for administrative supplements in response to PA-20-222, "Research Supplements to Promote Diversity in Health-Related Research." The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-20-031 for details) and encourages institutions to diversify their student populations by enhancing the participation of individuals from groups that are underrepresented in the biomedical, clinical, behavioral, and social sciences. Goal 1 of The National Plan to Address Alzheimers Disease is to prevent and effectively treat AD/ADRD by 2025. This initiative addresses the critical need to increase the number of health professionals who are trained to meet the expanding demand for cognitive impairment and dementia diagnosis, care, and clinical research to meet Goal 1. Program Directors/Principal Investigators (PD/PI) of active AD/ADRD research grants are thus encouraged to identify eligible individuals, including those from underrepresented groups, for support and mentorship under the auspices of this supplement opportunity. Individuals from the identified groups are eligible throughout the training continuum from high school to the faculty level. The activities proposed in the supplement application must fall within the scope and advance the objectives of the parent grant and support the research training and professional development of the supplement candidate. PIs must reference this Notice in the cover letter and application. For further guidance on submitting a responsive NINDS diversity supplement please visit this link: https://www.ninds.nih.gov/Funding/Training-Career-Development/Award/SUP….

Notice Change: Late Application Policy September 28, 2020, Application Due Date RFA-NS-21-002 NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)" Notice Number: NOT-NS-20-098 Key Dates Release Date: August 11, 2020 Related Announcements RFA-NS-21-002 - NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform applicants a change the late application policy the September 28, 2020, Application Due Date RFA-NS-21-002 "NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)". NINDS understands the public health emergency related the Coronavirus Disease 2019) adversely affect applicants' ability submit applications a timely manner. Late applications be accepted through 5:00 PM local time October 13, 2020, RFA-NS-21-002 "NINDS Exploratory Grant Program Parkinson's Disease Research P20- Clinical Trial Optional)". late applications submitted after October 13, 2020 be considered. cover letter citing Notice NOT-NS-20-098) be submitted, it not required. RFA modified no longer state, "No late applications be accepted this Funding Opportunity Announcement." Application Due Date(s) September 28, 2020 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Application Due Date(s) September 28, 2020 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: Beth-Anne.Sieber@nih.gov

Notice Change Key Dates PAR-18-563 NIH StrokeNet Small Business Innovation Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention U44 - Clinical Trial Optional)" Notice Number: NOT-NS-20-099 Key Dates Release Date: August 11, 2020 Related Announcements PAR-18-563 - NIH StrokeNet Small Business Innovation Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention U44 - Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-563 "NIH StrokeNet Small Business Innovation Clinical Trials Biomarker Studies Stroke Treatment, Recovery, Prevention U44 - Clinical Trial Optional)". Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date: April 5, 2021. Changes the FOA shown below bold italics. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 6, 2021 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. *** Note new SBIR/STTR Standard Due Dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date April 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Claudia Scala Moy, Ph.D.  National Institute Neurological Disorders & Stroke NINDS) Telephone: 301-496-9135  Email: moyc@ninds.nih.gov

Notice Change Key Dates PAR-18-628 NeuroNEXT Small Business Innovation Clinical Trials U44 Clinical Trial Optional)" Notice Number: NOT-NS-20-090 Key Dates Release Date: August 11, 2020 Related Announcements PAR-18-628 - NeuroNEXT Small Business Innovation Clinical Trials U44 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-628 "NeuroNEXT Small Business Innovation Clinical Trials U44 Clinical Trial Optional)(changes shown below bold italics). This Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date: April 5, 2021. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 6, 2021 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date April 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Codrin Lungu, MD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: lunguci@ninds.nih.gov

Notice Change: Late Application Policy September 28, 2020, Application Due Date RFA-NS-21-001 NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)" Notice Number: NOT-NS-20-097 Key Dates Release Date: August 11, 2020 Related Announcements RFA-NS-21-001 - NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform applicants a change the late application policy the September 28, 2020, Application Due Date RFA-NS-21-001 "NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)". NINDS understands the public health emergency related the Coronavirus Disease 2019) adversely affect applicants' ability submit applications a timely manner.  Late applications be accepted through 5:00 PM local time October 13, 2020, RFA-NS-21-001 "NINDS Morris K. Udall Centers Excellence Parkinson's Disease Research P50 Clinical Trial Optional)".  late applications submitted after October 13, 2020 be considered. cover letter citing Notice NOT-NS-20-097) be submitted, it not required. the September 28, 2021, September 28, 2022, application due date(s), NIH Policy Late Submission Grant Applications NOT-OD-15-039 applies. RFA modified no longer state, "No late applications be accepted this Funding Opportunity Announcement."  Application Due Date(s) September 28, 2020, September 28, 2021, September 28, 2022 applications due 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Application Due Date(s) September 28, 2020, September 28, 2021, September 28, 2022 applications due 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Beth-Anne Sieber, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 Email: Beth-Anne.Sieber@nih.gov

Notice Change Key Dates PAR-18-528 NeuroNEXT Clinical Trials U01 Clinical Trial Optional)" Notice Number: NOT-NS-20-084 Key Dates Release Date: August 10, 2020 Related Announcements PAR-18-528 - NeuroNEXT Clinical Trials U01 Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-528 "NeuroNEXT Clinical Trials U01 Clinical Trial Optional)" changes show below bold italics). Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date: February 5, 2021 Renewal, Resubmission, Revision Due Date: March 5, 2021. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 8, 2021 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply , 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date March 6, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Codrin Lungu, MD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: lunguci@ninds.nih.gov